WZB117
WZB117 (CAS 1223397-11-2) is a small-molecule inhibitor that targets glucose transporter 1 (GLUT1), a membrane protein responsible for basal glucose uptake essential to cellular bioenergetics. WZB117 selectively suppresses GLUT1-mediated glucose transport, exhibiting an IC50 of approximately 0.6 μM in various cancer cell lines. In vitro studies demonstrate that exposure to WZB117 reduces GLUT1 protein levels, intracellular ATP content, and expression of glycolytic enzymes, triggering activation of AMP-activated protein kinase (AMPK), downregulation of cyclin E2, reduced phosphorylated retinoblastoma, cell cycle arrest, senescence, and cell death by necrosis. In vivo, administration of WZB117 significantly decreases tumor growth in A549 lung cancer xenograft models, indicating its potential utility as a research tool in cancer metabolism studies.
- 1. Nan Jing, Jiaxing Song, et al. "Glycosylation of anthocyanins enhances the apoptosis of colon cancer cells by handicapping energy metabolism." BMC Complement Med Ther. 2020 Oct 15;20(1):312. PMID: 33059637
- 2. Li Y, Hong W, et al. "Photothermally triggered cytosolic drug delivery of glucose functionalized polydopamine nanoparticles in response to tumor microenvironment for the GLUT1-targeting chemo-phototherapy." J Control Release. 2019 Nov 26. pii: S0168-3659(19)30690-X. PMID: 31783048
| Storage | Store at -20°C |
| M.Wt | 368.3 |
| Cas No. | 1223397-11-2 |
| Formula | C20H13FO6 |
| Synonyms | Glucose Transporter Inhibitor IV |
| Solubility | insoluble in H2O; ≥18.4 mg/mL in DMSO; ≥42.6 mg/mL in EtOH |
| Chemical Name | 3-hydroxy-benzoic acid, (3-fluoro-1,2-phenylene)ester |
| SDF | Download SDF |
| Canonical SMILES | OC1=CC=CC(C(OC2=CC=CC(F)=C2OC(C3=CC(O)=CC=C3)=O)=O)=C1 |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
